<DOC>
	<DOCNO>NCT01684722</DOCNO>
	<brief_summary>The VITamin D OmegA-3 TriaL ( VITAL ; NCT 01169259 ) randomize clinical trial 20,000 U.S. men woman investigate whether take daily dietary supplement vitamin D3 ( 2000 IU ) fish oil ( 1 gram omega-3 fatty acid ) reduces risk develop cancer , heart disease , stroke people prior history illness . This ancillary study conduct among participant VITAL history diabetes examine whether vitamin D fish oil prevents development progression diabetic kidney disease .</brief_summary>
	<brief_title>Vitamin D Omega-3 Trial Prevent Treat Diabetic Kidney Disease</brief_title>
	<detailed_description>This ancillary study VITamin D OmegA-3 TriaL ( VITAL ) test whether vitamin D3 , omega-3 fatty acid , prevent development progression diabetic kidney disease ( DKD ) . Persons diabetes high risk kidney disease . In 2005-2008 , prevalence DKD among people type 2 diabetes United States 34.5 % . Moreover , 1988-1994 2005-2008 , prevalence DKD United States grow 34 % 6.9 million people . DKD lead cause end stage renal disease develop world potent amplifier cardiovascular disease risk . Vitamin D omega-3 fatty acid promise intervention DKD prevention treatment , base result animal-experimental model early human study . Because intervention relatively safe , inexpensive , widely available , may offer opportunity substantially reduce burden DKD large population . This VITAL ancillary study test whether vitamin D3 and/or omega-3 fatty acid prevent progression albuminuria loss glomerular filtration rate , two complementary manifestation DKD , 3 year treatment . In VITAL , 20,000 participant randomly assign 2x2 factorial design vitamin D3 ( cholecalciferol ) 2000 IU daily versus placebo , eicosapentaenoic acid 465 mg plus docosahexaenoic acid 375 mg daily versus placebo , follow mean 5 year assess effect cardiovascular disease cancer event . This ancillary study identify recruit sub-cohort VITAL participant diabetes baseline ascertain effect study intervention albuminuria glomerular filtration rate group . First morning void collect baseline year 3 measurement urine albumin-creatinine ratio . Blood sample collect simultaneously measurement estimate glomerular filtration rate ( use serum creatinine cystatin C ) relevant biomarkers . This VITAL ancillary study design determine whether vitamin D3 and/or omega-3 fatty acid causal clinically relevant effect development progression DKD .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Participants VITAL ( NCT 01169259 ) selfreported physician diagnosis diabetes eligible participate ancillary study . Type 1 diabetes Diabetes pregnancy Known cause kidney disease diabetes History kidney transplantation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>vitamin D3</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>fish oil</keyword>
	<keyword>diabetes</keyword>
	<keyword>kidney disease</keyword>
	<keyword>albuminuria</keyword>
	<keyword>urine albumin excretion</keyword>
	<keyword>glomerular filtration rate</keyword>
	<keyword>diabetic kidney disease</keyword>
</DOC>